Deep-layer Microvasculature Dropout in Preperimetric Glaucoma Patients.


Journal

Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 25 3 2020
medline: 1 12 2020
entrez: 25 3 2020
Statut: ppublish

Résumé

To compare disease severity between preperimetric primary open-angle glaucoma (POAG) patients with and without deep-layer microvasculature dropout. Ninety-four eyes of 94 preperimetric POAG patients with β-zone parapapillary atrophy (βPPA) were categorized according to the presence of deep-layer microvasculature dropout defined as a complete loss of microvasculature within the choroid or scleral flange on optical coherence tomography angiography. Parameters representing disease severity, that is, visual field (VF) mean deviation (MD), global and sectoral (6-sector) retinal nerve fiber layer (RNFL) thickness, and other factors including age, focal lamina cribrosa (LC) defect, width of βPPA with and without Bruch membrane (BM) (βPPA+BM and βPPA-BM), and optic disc hemorrhage were compared between eyes with and without dropout. Deep-layer microvasculature dropout was observed in 33 preperimetric POAG eyes (35.1%). Eyes with dropout had significantly thinner RNFL in all areas except the inferonasal sector, worse VF MD, and higher prevalence of focal LC defect, and larger βPPA-BM (P<0.05), whereas the 2 groups did not differ in age, disc hemorrhage, or βPPA+BM width (P>0.05). In the multivariable logistic regression, worse VF MD [odds ratio (OR), 1.485; P=0.045], thinner RNFL (OR, 1.141; P<0.001), and higher prevalence of focal LC defect (OR, 6.673; P<0.001) were significantly associated with dropout. Deep-layer microvasculature dropout was observed in a considerable number of preperimetric POAG eyes, and worse disease severity was associated with dropout. Future studies elucidating the pathogenic role of deep-layer microvasculature dropout in the development and progression of glaucoma are warranted.

Identifiants

pubmed: 32205833
doi: 10.1097/IJG.0000000000001489
pmc: PMC7272281
mid: NIHMS1573665
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-428

Subventions

Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY011008
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY019869
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027510
Pays : United States

Références

Ophthalmology. 2017 Nov;124(11):1589-1599
pubmed: 28676279
Ophthalmology. 2016 Dec;123(12):2509-2518
pubmed: 27769587
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1995-2004
pubmed: 29677362
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5673-5680
pubmed: 29101405
Ophthalmology. 2017 Aug;124(8):1209-1217
pubmed: 28433445
Ophthalmology. 2014 Feb;121(2):498-507
pubmed: 24289917
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):901-912
pubmed: 30835291
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT27-36
pubmed: 27409483
Arch Ophthalmol. 2012 May;130(5):552-9
pubmed: 22232364
Ophthalmology. 2016 Sep;123(9):1965-73
pubmed: 27320517
JAMA Ophthalmol. 2019 Jul 1;137(7):810-816
pubmed: 31120486
Am J Ophthalmol. 2015 Jan;159(1):160-8.e1-2
pubmed: 25448320
J Glaucoma. 2017 Mar;26(3):216-222
pubmed: 27875487
Ophthalmology. 2014 Aug;121(8):1524-30
pubmed: 24697910
J Glaucoma. 2018 Jun;27(6):543-551
pubmed: 29613982
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3768-3775
pubmed: 31499532
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3694-3701
pubmed: 30029256
Ophthalmology. 2016 Nov;123(11):2309-2317
pubmed: 27592175
Ophthalmology. 2018 Jul;125(7):1003-1013
pubmed: 29486903
Am J Ophthalmol. 2006 Oct;142(4):576-82
pubmed: 17011848
Am J Ophthalmol. 2016 Aug;168:237-249
pubmed: 27296492
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT451-9
pubmed: 27409505
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1621-1627
pubmed: 28297027
Am J Ophthalmol. 1989 May 15;107(5):453-64
pubmed: 2712129
Am J Ophthalmol. 2019 Apr;200:65-75
pubmed: 30578786
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4709-18
pubmed: 19443718
Ophthalmology. 2013 Sep;120(9):1790-7
pubmed: 23672970
Ophthalmology. 2012 Apr;119(4):738-47
pubmed: 22222150
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):741-8
pubmed: 10711689
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3004-3010
pubmed: 28605811

Auteurs

Min Hee Suh (MH)

Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.

Jeong Ho Na (JH)

Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.

Linda M Zangwill (LM)

The Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA.

Robert N Weinreb (RN)

The Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH